The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...

Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...